CLINICAL SIGNIFICATION OF THE CONTENT OF STEM CELLS IN BRAIN TUMORS
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-21-3-2019-g.7223Keywords:
gliomas, stem cells, CD133, lymphocytes, neutrophils, platelets.Abstract
Summary. Objective: to analyze the dependence of histostructure and the degree of malignancy of brain tumors on
the expression level of CD133 antigens in brain tumors,
as well as the ratios of different hematopoietic germ cells
(granulocytes, lymphocytes— Lph, platelets—Plt) in peripheral blood (PB). Object and methods: the parameters of PB of 46 patients with glial tumors were studied.
The expression of CD133 on tumor cells was determined
in the initial suspension of the operative material using
McAb to CD133 (Millipore) using flow cytometry. The
determination of PB indices was carried out in the preoperative period using the automatic hematology analyzer MINDRAY BC 3000 plus. Absolute amounts of Plt,
neutrophils (Nph) and Lph, as well as the ratio of absolute amounts of Plt/Lph and Plt/Nph and relative content of Nph/Lph were determined. Results: it was established that in glioblastomas (degree IV of anaplasia) the
expression level of CD133 is 2–3 times higher than with
gliomas degree I–III of anaplasia. In the group of patients with high CD133 expression, there was a significant decrease in the relative content of Lph in PB compared with the group of patients with low CD133+ cells.
A negative correlation (r = –0.40) was established between the number of CD133+ cells in the tumor and the
relative content of Lph in the PB; the positive correlation (r = 0.45) was established by the relative content of
Nph. The ratio Nph/Lph was significantly higher with a
high content of CD133+ cells compared to low values of
CD133+ (4.4 ± 0.9 and 2.4 ± 0.7, respectively). Conclusions: the content of CD133+ stem cells in brain gliomas
increases with increasing degree of anaplasia. The number
of CD133+ cells in the tumor tissue correlates with the relative content of Lph (negative correlation) and Nph (positive correlation) in the PB of patients with brain tumors.
References
Dahlrot RH, Hansen S, Jensen SS, et al. Clinical value of 133 and nestin in patients with glioma: a population based study. J Clin Exp Pathol 2014; 7 (7): 3739–51.
Dey M, Ulasov IV, Tyler MA, et al. Cancer stem cells: The final frontier for glioma virotherapy. Stem Cell Rev 2011; 7 (1): 119–29.
Ahmed SI, Javed G, Laghari AA, et al. CD133 expression in glioblastoma multiforme: a literature review. Cureus 2018; 10 (10): e3439.
Flavahan WA, Drier Y, Liau BB, et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 2016; 529 (758u): 110–4.
Bien-Moller S, Balz E, Herzog S, et al. Association of glioblastoma multiforme stem cell characteristics differentiation and microglia markers genes with patient survival. Stem Cells Int 2018; 96: 28289.
Zhang J, Cai H, Sun L, et al. LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt/β-catenin pathway and predicts poor survival of glioma patients. J Exp Clin Cancer Res 2018; 37 (1): 225.
Hai L, Zhang Ch, Li T, et al. Notch is a prognostic factor that is distinctly activated in the classical and proneural subtype of glioblastoma and that promotes glioma cell survival via the NFkβ-p65 pathway. Cell Death Dis 2018; 9 (2): 158.
Verhaak RGW, Hoadley CA, Purdom E, et al. An integrated genomic analysis indentifies clinically relevant subtypes of glioblastoma characterized by abnormal lities in PDGFRA, IDHI, RGFR and NF1. Cancer Cell 2010; 17 (1): 98–110.
Wang R, Cas H, Zhang Ch, et al. Molecular and clinical characterization of PTPN2 expression from RNA seq data of 996 brain gliomas. J Neuroinflammation 2018; 15: 145.
Pinegin BV, Yrilin AA, Semenova AV, et al. Primenenie protochnoy cytometrii dly ocenki funkcionalnoy aktivnosti immynn systemy cheloveka/ Posobie dly vrachey/ M. 2001. 58. (in Russian).
Gnedkova IA, Lisyaniy NI, Shmeleva AA, et al. Ration of innate and adaptive immunity cells in peripheral blood depending on histogenesis and degree of anaplasia of brain tumors. Onkology 2018; 20 (1): 28–33 (in Russian).
Lisyanyi NI, Gnedkova I.A,Belskay LN, et al. Content of stem tumor CD133+ and CD15+ cells in gliomas and lymphocytes in peripheral blood of patients with gliomas of different level anaplasia. Onkology 2016; 18 (1): 44–7 (in Russian).
Kim WT, Ryu CJ. Cancer stem cell surface markers on normal stem cells. BMB Rep 2017; 50 (6): 285–98.
Glumac PM, LeBeau AM. The role of CD133 in cancer: a concise review. Clin Transl Med 2018; 7: 18.
Gieden PR, Schulte BM, Kers-Rebel ED, et al. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100 A8/9 and arginase a suppress T cell function. Neuro Oncol 2016; 18 (9): 1253–64.
Mostofa AGM, Pungamuru SR, Madolla HR. The process and regulatory components of inflammation in brain ocogenesis. Biomolecules 2017; 7 (2): 34.
Gieryng A, Kaminska B. Myeloid-derived suppressor cells in gliomas. Contemp Oncol (Pozn) 2016; 20 (5): 345–51.
Hung Y, Rajappa P, Hu W, et al. A proangiogenic signaling axis in myeloid cells promotes malignant progression of glioma. J Clin Invest 2017; 127 (15): 1826–38.
Otvos B, Silver DJ, Mulkems-Habert EE, et al. Cancer stem cells-secreted macrophages migration inhibitory factor stimulates myeloid derived suppressor cell function and facilitates glioblastoma immune evasion. Stem Cells 2016; 34 (8): 2026–39.
